Is there evidence to support an 18-month interval between IV Zoledronate 5 mg treatments for osteoporosis in men or postmenopausal women?
Abstract
Eighteen-month dosing of zoledronate is supported by evidence for reducing fracture risk in postmenopausal women, although long-term outcomes and applicability to men need more study.
Fields of Study & Subjects
Bone health and osteoporosis research
Bone health and treatments
Menopause: Health Impacts and Treatments
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 27 January 2026